PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.264
https://www.valueinhealthjournal.com/article/S1098-3015(19)32642-7/fulltext
Title :
PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32642-7&doi=10.1016/j.jval.2019.09.264
First page :
Section Title :
Open access? :
No
Section Order :
10208